Richard G. Harris, MD, led a panel discussion on “Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19” for the Grand Rounds in Urology audience in July, 2020.
How to cite: Harris, Richard G. Langford, Timothy D. Saltzstein, Daniel R. Crawford, E. David. “Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19” July, 2020. Accessed Apr 2024. https://grandroundsinurology.com/panel-discussion-on-challenges-of-managing-androgen-deprivation-therapy-patients-during-covid-19/
Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19 – Summary:
Richard Harris, MD, President of LUGPA and CEO of UroPartners, moderates a discussion between Daniel R. Saltzstein, MD, from Urology San Antonio, and Timothy D. Langford, MD, from Arkansas Urology, about modifications to their ADT treatment regimens during COVID-19. Dr. Saltzstein discusses a typical case in his practice: men with high-risk, de novo prostate cancer that he does not plan on keeping on a lifetime course of ADT. In this case, he pairs ADT with IMRT in a 6-month depot formulation of an agonist to avoid frequent visits to the office. Dr. Langford’s practice is following a similar approach, switching from 3-month injections to 6 months. They also discuss telehealth solutions for minimizing patient visits, such as follow-ups for blood draws, PSA results, and prostatectomies, and further concur that CMS needs to move more quickly to make telehealth more accessible for physicians and patients.
To expand your knowledge of androgen deprivation therapy, visit our ADT Next Generation Learning Center.
